본문 바로가기

Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 35Scopus 37
FWCI (Scopus)
2.84
JCR IF
JCR 2024 4.9
ISSN
1661-6596

저자

  1. 장정윤제1저자Pusan Natl Univ, Coll Pharm, Res Inst Drug Dev, Dept Pharm, Busan 46241, South Korea
  2. Kim, DonghwanKorea Food Res Inst, Funct Food Mat Res Grp, Wanju Gun 55365, Jeollabuk Do, South Korea
  3. 임은옥교신저자Pusan Natl Univ, Coll Pharm, Res Inst Drug Dev, Dept Pharm, Busan 46241, South Korea
  4. 김남득교신저자Pusan Natl Univ, Coll Pharm, Res Inst Drug Dev, Dept Pharm, Busan 46241, South Korea

초록

Topoisomerase II inhibitors, particularly etoposide, have long been integral to the treatment of lung cancer, especially small cell lung cancer. This review comprehensively examines the mechanisms of action of etoposide, its clinical efficacy, and its role in current lung cancer treatment regimens. Etoposide exerts its anticancer effects by inducing DNA strand breaks through the inhibition of topoisomerase II, leading to cancer cell apoptosis. Despite their widespread use, challenges such as drug resistance, toxicity, and limited efficacy in non-small cell lung cancer have spurred ongoing research on combination therapies and novel drug formulations. Emerging therapeutic strategies include the integration of etoposide with immunotherapy, targeted therapies, and novel drug delivery systems aimed at enhancing the therapeutic window and overcoming drug resistance. This article aims to inform the development of more effective treatment strategies by providing a critical overview of the clinical applications of etoposide and exploring future directions for lung cancer therapy.

키워드

anticanceretoposidelung cancertopoisomerase II inhibitorsPHASE-III TRIAL1ST-LINE TREATMENTTHORACIC RADIOTHERAPYCHEMOTHERAPYCARBOPLATINCISPLATINCISPLATIN/ETOPOSIDERESISTANCEINHIBITORSREGIMEN

식별자

Scopus EID
2-s2.0-85216035022
WoS UID
001404306700001